• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
OpGen, Inc. (OPGN) Stock Price, News & Analysis

OpGen, Inc. (OPGN) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.50

-$0.31

(-17.13%)

Day's range
$1.5
Day's range
$1.7
50-day range
$1.4
Day's range
$2.24
  • Country: US
  • ISIN: US68373L4068
52 wk range
$1.4
Day's range
$9.9


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -78.56
  • Piotroski Score 3.00
  • Grade Neutral
  • Symbol (OPGN)
  • Company OpGen, Inc.
  • Price $1.50
  • Changes Percentage (-17.13%)
  • Change -$0.31
  • Day Low $1.50
  • Day High $1.70
  • Year High $9.90

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/15/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.67
  • High Stock Price Target $0.67
  • Low Stock Price Target $0.67
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$41.47
  • Trailing P/E Ratio -0.06
  • Forward P/E Ratio -0.06
  • P/E Growth -0.06
  • Net Income $-32,668,530

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

OpGen, Inc. Frequently Asked Questions

  • What is the OpGen, Inc. stock price today?

    Today's price of OpGen, Inc. is $1.50 — it has decreased by -17.13% in the past 24 hours. Watch OpGen, Inc. stock price performance more closely on the chart.

  • Does OpGen, Inc. release reports?

    Yes, you can track OpGen, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the OpGen, Inc. stock forecast?

    Watch the OpGen, Inc. chart and read a more detailed OpGen, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is OpGen, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by OpGen, Inc. stock ticker.

  • How to buy OpGen, Inc. stocks?

    Like other stocks, OPGN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is OpGen, Inc.'s EBITDA?

    OpGen, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in OpGen, Inc.’s financial statements.

  • What is the OpGen, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -9.5568963701, which equates to approximately -955.69%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in OpGen, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including OpGen, Inc.'s financials relevant news, and technical analysis. OpGen, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for OpGen, Inc. stock currently indicates a “sell” signal. For more insights, review OpGen, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.